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Abstract
Purpose The current study was conducted to determine the effects of coenzyme Q10 (CoQ10) supplementation on glycemic 
control and markers of lipid profiles risk in diabetic hemodialysis (HD) patients.
Methods This randomized, double blind, placebo-controlled clinical trial was performed among 60 diabetic HD patients. 
Subjects were randomly allocated into two groups to take either 120 mg/day of CoQ10 supplements or placebo (n = 30 each 
group) for 12 weeks.
Results After 12 weeks of intervention, CoQ10 supplementation, compared with the placebo, resulted in a significant 
decrease in serum insulin concentrations (− 2.5 ± 4.0 vs. + 2.8 ± 5.3 µIU/mL, P < 0.001), homeostasis model of assessment-
estimated insulin resistance (− 0.9 ± 2.1 vs. + 1.2 ± 3.0, P = 0.002), and significant increase in the quantitative insulin sen-
sitivity check index (+ 0.009 ± 0.01 vs. − 0.02 ± 0.05, P = 0.003). In addition, a trend toward a greater decrease in serum 
triglycerides (− 5 ± 53 vs. + 17 ± 44, P = 0.078) and VLDL-cholesterol levels (− 0.9 ± 10 vs. + 3 ± 9, P = 0.078) was observed 
in the CoQ10 group compared to the placebo group. We did not observe any significant effect of CoQ10 supplementation 
on fasting glucose, HbA1c and other lipid profiles compared with the placebo.
Conclusions Overall, our study supported that CoQ10 supplementation to diabetic HD patients for 12 weeks had beneficial 
effects on markers of insulin metabolism, but did not affect fasting glucose, HbA1c, and lipid profiles. Clinical registration 
http://www.irct.ir: IRCT2016081811763N30.
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Introduction
The prevalence of diabetes and the incidence of diabetic 
nephropathy (DN) have increased worldwide [1]. Diabetic 
patients constitute the largest proportion of individuals with 
end-stage renal disease (ESRD) requiring dialysis or trans-
plantation. In developed countries, this status accounts for 
up to 50% of ESRD patients [1]. Earlier, it was reported that 
(HD) patients are correlated with multiple events such as 
metabolic disorders, especially insulin resistance and dyslip-
idemia, malnutrition and inflammation, which in turn influ-
ence the health-related quality of life aspects in the diabetic 
HD population [2–6]. CoQ10 supplementation improved 
immune and autonomic function in ESRD [7].
Clinical evidence has demonstrated that increased inflam-
matory cytokines, a non-traditional risk factor for cardio-
vascular diseases, are common in dialysis patients and may 
result in progressive atherosclerosis [8, 9]. Previous studies 
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have reported that CoQ10 levels in HD patients were sig-
nificantly lower than those of controls [10, 11]. In addition, 
in a study by Macunluoglu et al. [12], it was observed that 
circulating CoQ10 levels were associated with the coronary 
flow reserve in HD patients, while another study did not 
support the association between CoQ10 supplementation 
and coronary function [13]. Furthermore, CoQ10 has been 
recorded to be inadequate in diabetic states [14]. Although 
some studies showed significant associations between Q10 
and stress oxidative biomarkers [15–17], others did not con-
firm such associations [18, 19]. The CoQ10 deficiency may 
be associated with the impairment of β-cells and the devel-
opment of insulin resistance [20] due to increased free radi-
cals and other biomarkers of oxidative stress, and impaired 
mitochondrial substrate metabolism [21]. Some studies have 
demonstrated the beneficial effects of CoQ10 supplementa-
tion on glycemic control, lipid profiles and clinical outcomes 
in diseases related to metabolic disorders. For example, 
CoQ10 supplementation at a dosage of 200 mg/day to over-
weight and obese subjects with diabetes for 12 weeks sig-
nificantly reduced HbA1c, although no significant changes 
were observed in fasting glucose and insulin, and insulin 
resistance [22]. In addition, the administration of 100 mg 
CoQ10 supplements to patients with metabolic syndrome for 
8 weeks had beneficial effects on markers of insulin metabo-
lism, but did not affect lipid profiles [23].
CoQ10 intake may improve metabolic profiles through 
the modulation of insulin and adiponectin receptors, as well 
as glucose transporters, improving the redox system and adi-
pocytokines [24]. This evidence suggests the importance of 
CoQ10 supplementation on diabetic HD patients. To the best 
of our knowledge, data on the effects of CoQ10 supplemen-
tation on glycemic control and markers of lipid profiles in 
diabetic HD patients are scarce. Therefore, the present study 
was conducted to determine the effects of CoQ10 supple-
mentation on glycemic control and markers of lipid profile 
in diabetic HD subjects.
Materials and methods
Trial design and participants
This study was a 12-week randomized, double-blinded, 
placebo-controlled clinical trial registered with the website 
for registration of clinical trials in Iran (http://www.irct.ir: 
IRCT2016081811763N30). Sixty diabetic HD subjects, 
aged 18–80 years who were referred to the Akhavan Clinic 
in Kashan, Iran, from April 2017 to October 2017, were 
included in this trial. The study protocol was approved by 
the research ethics committee of Isfahan University of Medi-
cal Sciences (IUMS) and informed consent was taken from 
all participants. Exclusion criteria were as follows: taking 
antioxidant and/or anti-inflammatory supplements, and tak-
ing immunosuppressive medications within 3 months prior 
to enrollment in the study.
Study procedures
Subjects were randomly divided into two groups to take 
either 60 mg CoQ10 (n = 30) or placebo (n = 30) twice a day 
for 12 weeks. We used 60 mg of CoQ10 for 12 weeks based 
on previous studies on HD patients [6, 25–27]. The randomi-
zation process was conducted using computer-generated ran-
dom numbers by a trained staff at the clinic, blinded to both 
participants and researchers. CoQ10 and placebo capsules 
were produced by Zahravi, Tabriz, Iran and Barij Essence 
Pharmaceutical Company, Kashan, Iran, approved by the 
Food and Drug Administration. They were completely iden-
tical in terms of their appearance, color, shape, size, smell, 
taste, and packaging.
To increase compliance rates, all participants received 
messages on their cell phones every day to remind them of 
taking their capsules. The compliance rate was evaluated by 
counting the remaining supplements and subtracting them 
from the number of supplements provided to the partici-
pants. Subjects were requested not to change their routine 
physical activity or usual dietary intakes throughout the 
study and not to consume any supplements other than the 
one provided to them by the investigators as well as not to 
take any medications that might affect the outcomes during 
the 12-week intervention. The strategies for managing diabe-
tes in the experimental and control group were steady during 
the study. Insulin therapy and dietary advice were used to 
manage diabetic patients. We excluded subjects during the 
trial if they required changing their medications.
Patients who enrolled in the study had Kt/V of at least 
0.9 and dialyzed 2 or 3 times a week by Gambro AK 95 and 
Gambro AK 96 dialyzer, about 3–4 h each time and their 
session lengths were constant during the study. The blood 
flow rate range determined according to patients Kt/V and 
it did not change from the baseline to the end of the study. A 
3-day food record was obtained at weeks 0, 5, 8, and 12 of 
the intervention and macro- and micro-nutrient intakes were 
determined using the Nutritionist IV software [28] (First 
Databank, San Bruno, CA, USA) modified for Iranian foods.
Assessment of outcomes
Primary outcome measurements were insulin metabolism 
and secondary outcome measurements were lipid fractions. 
At the baseline and after the end of treatment, 10 mL fast-
ing blood samples were obtained from each patient before 
the dialysis session after the weekend at Akhavan Clinic 
laboratory in Kashan, Iran. To quantify fasting plasma glu-
cose (FPG) and serum lipid profiles, we used enzymatic kits 
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of Pars Azmun (Tehran, Iran) with inter- and intra-assay 
coefficient variances (CVs) of less than 5%. Serum insulin 
levels were assessed using an ELISA kit (Monobind, Cali-
fornia, USA) with inter- and intra-assay CVs of 2.8–4.9%, 
respectively. The suggested formulas were used to deter-
mine the homeostasis model of assessment-estimated insu-
lin resistance (HOMA-IR) and the quantitative insulin sen-
sitivity check index (QUICKI) [29]. Overall, hemoglobin 
A1c  (HbA1C) was determined by the Glycomat kit (Bio-
codeHycel, Massy, France) using the method of exchange 
chromatography.
Sample size
To compute the sample size, the recommended formula 
for the parallel-design randomized controlled trial was 
used based on type one (α) and type two errors (β) as 0.05 
and 0.20 (power = 80%), respectively. Based on a previous 
investigation [23], we used a standard deviation of 2.5 and 
a difference in mean (d) of 1.68, considering HOMA-IR as 
the key variable. Based on the sample size calculation, we 
needed 25 subjects in each treatment group, allowing for 
20% dropout in each group, and the final sample size was 
considered to be 30 participants in each group.
Statistical methods
The normality of study variables was determined using 
the Kolmogorov–Smirnov test. Anthropometric measures 
as well as macro- and micro-nutrient dietary intakes were 
compared between the two groups, using the independent 
samples t-test. Categorical variables were compared by the 
Pearson Chi square test. To determine the effects of CoQ10 
supplementation on metabolic profiles, we used one-way 
repeated measures analysis of variance. Analysis of covari-
ance (ANCOVA) was used to identify any differences 
between the two groups at the end of the study, adjusting 
for baseline values, BMI, and age. P-values < 0.05 were con-
sidered statistically significant. All statistical analyses were 
done using the Statistical Package for Social Science version 
18 (SPSS Inc., Chicago, Illinois, USA).
Results
In the present study, 60 diabetic HD patients [CoQ10 
(n = 30) and placebo (n = 30)] completed the trial (Fig. 1). 
On average, the rate of compliance in the current study was 
high, such that higher than 90% of the supplements were 
taken throughout the study in both groups. No side effects 
were reported following the administration of CoQ10 in dia-
betic HD patients throughout the study.
Distribution of gender, participants’ mean age, height, 
Kt/V, baseline and end-of-treatment weight, and BMI were 
not statistically different between the two groups (Table 1).
We observed no significant change in dietary macro- and 
micro-nutrient intakes between the two groups throughout 
the trial (Data not shown).
After 12 weeks of intervention, CoQ10 supplementa-
tion compared with the placebo resulted in a significant 
Fig. 1  Summary of patient flow 
diagram
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decrease in serum insulin concentrations (− 2.5 ± 4.0 vs. 
+ 2.8 ± 5.3 µIU/mL, P < 0.001), HOMA-IR (− 0.9 ± 2.1 vs. 
+ 1.2 ± 3.0, P = 0.002), and a significant increase in QUICKI 
(+ 0.009 ± 0.01 vs. − 0.02 ± 0.05, P = 0.003) (Table 2). In 
addition, a trend toward a greater decrease in serum triglyc-
erides (− 5 ± 53 vs. + 17 ± 44, P = 0.078) and VLDL-choles-
terol levels (− 0.9 ± 10 vs. + 3 ± 9, P = 0.078) was observed 
in the CoQ10 group compared to the placebo group. We did 
not see any significant effect of CoQ10 supplementation on 
fasting glucose, HbA1c, and other lipid profiles compared 
with the placebo.
We adjusted the analysis for baseline values of biochemi-
cal variables, age, and baseline BMI; however, our findings 
did not change (Table 3).
Discussion
Our study supported the fact that CoQ10 supplementation in 
HD patients for 12 weeks was associated with a significant 
reduction in serum insulin and HOMA-IR, and a significant 
increase in QUICKI compared with the placebo, but did not 
influence FPG, HbA1c, and lipid profiles.
HD subjects are susceptible to multiple metabolic dis-
turbances such as hyperinsulinemia and dyslipidemia [30]. 
Few human studies have reported the beneficial effects of 
CoQ10 supplementation on glycemic control in patients 
without HD. Gholnari et al. [31] demonstrated that CoQ10 
administration at a dosage of 100 mg/day for 12 weeks to 
DN patients had favorable effects on fasting glucose and 
markers of insulin metabolism. In addition, 200 mg/day of 
ubiquinol supplementation for 12 weeks to patients with 
type 2 diabetes mellitus (T2DM) resulted in a significant 
improvement in insulin production and/or secretion probably 
via stimulating ATP production in pancreatic beta cells [32]. 
Changes in glucose status and insulin resistance are recog-
nized at all stages of chronic kidney disease as well as ESRD 
[33, 34]. In chronic HD, hyperglycemia and insulin resist-
ance are independent non-traditional risk factors for cardio-
vascular mortality and are correlated with protein energy 
wasting, malnutrition, anemia, reduced physical activity, 
Table 1  General characteristics of study participants
Data are means ± SDs
BMI body mass index
a Obtained from independent t tests for quantitative and Chi square for 
qualitative variables between the two groups
Placebo group
(n = 30)
CoQ10 group
(n = 30)
Pa
Age (y) 64.8 ± 11.5 59.4 ± 12.2 0.082
Height (cm) 162.6 ± 10.8 167.2 ± 9.6 0.091
Weight at study baseline 
(kg)
70.8 ± 13.9 75.2 ± 12.8 0.200
Weight at end-of-trial (kg) 69.9 ± 13.3 74.9 ± 13.07 0.141
Weight change (kg) − 0.8 ± 5.3 − 0.2 ± 1.1 0.500
BMI at study baseline (kg/
m2)
26.6 ± 3.9 26.9 ± 3.9 0.790
BMI at end-of-trial (kg/m2) 26.2 ± 3.2 26.8 ± 4.0 0.541
BMI change (kg/m2) − 0.4 ± 2.1 − 0.08 ± 0.4 0.458
Gender (%)
 Male 18 (60.0) 22 (73.3%)
 Female 12 (40.0) 8 (26.7) 0.300
Kt/V 1.3 ± 0.2 1.3 ± 0.2 0.300
Table 2  Metabolic profiles at baseline and after the 12-weeks intervention in patients with diabetic hemodialysis that received either CoQ10 sup-
plements or placebo
Data are means ± SDs
FPG fasting plasma glucose, HOMA-IR homeostasis model of assessment-estimated insulin resistance, QUICKI quantitative insulin sensitivity 
check index
a Obtained from repeated measures ANOVA test
Placebo group (n = 30) CoQ10 group (n = 30) Pa
Baseline End-of-trial Change Baseline End-of-trial Change
FPG (mg/dL) 114.8 ± 61.5 125.2 ± 69.7 10.3 ± 55.9 130.6 ± 57.4 123.9 ± 40.6 − 6.7 ± 49.2 0.210
Insulin (µIU/mL) 13.4 ± 7.6 16.2 ± 7.9 2.8 ± 5.3 15.4 ± 6.3 12.9 ± 5.1 − 2.5 ± 4.0 < 0.001
HOMA-IR 3.8 ± 2.4 5.02 ± 3.4 1.2 ± 3.0 4.9 ± 2.9 4.0 ± 2.2 − 0.9 ± 2.1 0.002
QUICKI 0.3 ± 0.05 0.3 ± 0.03 − 0.02 ± 0.05 0.3 ± 0.02 0.3 ± 0.02 0.009 ± 0.01 0.003
HbA1c (%) 7.5 ± 1.7 7.4 ± 1.7 − 0.1 ± 1.5 7.2 ± 1.7 6.7 ± 1.6 − 0.5 ± 1.6 0.09
Triglycerides (mg/dL) 121 ± 66 139 ± 78 17 ± 44 135 ± 79 131 ± 64 − 5 ± 53 0.078
VLDL-cholesterol (mg/dL) 24 ± 13 28 ± 16 3 ± 9 27 ± 16 26 ± 13 − 0.9 ± 10 0.078
Total cholesterol (mg/dL) 143 ± 42 148 ± 44 5 ± 31 134 ± 32 138 ± 36 5 ± 31 0.870
LDL-cholesterol (mg/dL) 86 ± 35 87 ± 39 2 ± 27 76.±27 81 ± 34 5 ± 29 0.581
HDL-cholesterol (mg/dL) 33 ± 6 33 ± 7 − 0.3 ± 4 30 ± 6 31 ± 5 0.2 ± 5 0.581
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and accumulation of uremic toxins [35]. In a previous study 
that was conducted on subjects with T2DM who received 
CoQ10 (200 mg/day) for 12 weeks, no significant changes 
were observed in fasting glucose, insulin and HOMA-IR 
[22]. Anti-diabetic effects of CoQ10 may be due to increases 
in the enzyme activities of tyrosine kinase and phosphati-
dylinositol 3 kinase. The mentioned enzymes are involved in 
autophosphorylation of insulin receptors that consequently 
improve glucose uptake and inhibit gluconeogenesis in the 
liver [24]. In the present study, non-significant changes in 
HbA1C and FPG may be due to the dosage of CoQ10 or 
the relatively small sample size and the short duration of 
our trial. In addition, previous reports showed that treat-
ment with recombinant erythropoietin may affect HbA1C 
values in patients undergoing hemodialysis and underesti-
mate glycemic control in HD patients [36, 37]. However, in 
the present study, the same levels of erythropoietin therapy 
were used in the control and intervention group.
Our study showed that CoQ10 supplementation to HD 
patients for 12 weeks resulted in a trend toward a greater 
decrease in serum triglycerides and VLDL-cholesterol levels 
compared to the placebo group, but did not affect other lipid 
profiles. CoQ10 supplementation at a dosage of 150 mg/
day for 12 weeks in patients with T2DM had no favorable 
effects on lipid profiles [38]. Witting et al. [39] found that 
CoQ10 intake had no considerable effect on total cholesterol 
levels in apolipoprotein E gene knock-out mice. In another 
study, a 6-week CoQ10 treatment in a rat model of metabolic 
syndrome had no significant effect on dyslipidemia [40]. 
Moreover, Chew et al. [41] evaluated the effects of CoQ10 
and fenofibrate in patients with T2DM with left ventricular 
diastolic dysfunction. The result demonstrated that 200 mg/
day of CoQ10 supplements did not affect total-, HDL- and 
LDL-cholesterol levels [41]. This discrepancy between the 
current studies and others might be explained by distinct 
trial designs, small sample size, various dosages of CoQ10 
supplements, different forms of CoQ10 used, and character-
istics of the subjects. The normal baseline of lipid profiles in 
most of the study participants could be another explanation 
for these non-significant results.
One of the limitations of the study was the relatively 
short time of CoQ10 supplementation. Long-term inter-
ventions might result in significant (or more pronounced) 
effects in lipid profiles. Furthermore, the determination of 
gene expression profiles related to insulin and lipid pathways 
might have enabled us to better elucidate possible mecha-
nisms that connect CoQ10 and metabolic disorder in HD 
patients. In addition, we did not assess the serum levels of 
CoQ10 in our cohort and this might have better evaluated 
the patient’s adherence in our analysis. Overall, our study 
supported the fact that CoQ10 supplementation to diabetic 
HD patients for 12 weeks had beneficial effects on markers 
of insulin metabolism, but did not affect fasting glucose, 
HbA1c, and lipid profiles.
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